BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29857484)

  • 1. Design, Synthesis, and Evaluation of a New Series of Thiazole-Based Anticancer Agents as Potent Akt Inhibitors.
    Altıntop MD; Sever B; Akalın Çiftçi G; Özdemir A
    Molecules; 2018 May; 23(6):. PubMed ID: 29857484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
    Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
    Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
    Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
    Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell lung cancer.
    Orujova T; Ece A; Akalın Çiftçi G; Özdemir A; Altıntop MD
    Drug Dev Res; 2023 Apr; 84(2):185-199. PubMed ID: 36469421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New thiazole carboxamides as potent inhibitors of Akt kinases.
    Chang S; Zhang Z; Zhuang X; Luo J; Cao X; Li H; Tu Z; Lu X; Ren X; Ding K
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1208-12. PubMed ID: 22172705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors.
    Kaplancikli ZA; Altıntop MD; Atli O; Sever B; Baysal M; Temel HE; Demirci F; Ozdemir A
    Anticancer Agents Med Chem; 2017; 17(5):674-681. PubMed ID: 27491937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
    Turan-Zitouni G; Altıntop MD; Özdemir A; Kaplancıklı ZA; Çiftçi GA; Temel HE
    Eur J Med Chem; 2016 Jan; 107():288-94. PubMed ID: 26599534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
    Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
    Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
    Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
    Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some Thiazole Derivatives Combined with Different Heterocycles: Cytotoxicity Evaluation and Apoptosis Inducing Studies.
    Yurttaş L; Demir B; Çiftçi GA
    Anticancer Agents Med Chem; 2018; 18(8):1115-1121. PubMed ID: 29595114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
    Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
    Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
    Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
    Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR
    Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Evaluation of New Benzodioxole- Based Thiosemicarbazone Derivatives as Potential Antitumor Agents.
    Altıntop MD; Temel HE; Sever B; Akalın Çiftçi G; Kaplancıklı ZA
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27879683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazole-Based Thiosemicarbazones: Synthesis, Cytotoxicity Evaluation and Molecular Docking Study.
    Gomha SM; Abdelhady HA; Hassain DZH; Abdelmonsef AH; El-Naggar M; Elaasser MM; Mahmoud HK
    Drug Des Devel Ther; 2021; 15():659-677. PubMed ID: 33633443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors.
    Lei H; Hu G; Wang Y; Han P; Liu Z; Zhao Y; Gong P
    Arch Pharm (Weinheim); 2016 Aug; 349(8):651-61. PubMed ID: 27283017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
    Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.